Reports Q4 revenue $47.54M, consensus $45.29M. “2024 was a terrific year for Geron (GERN) and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly ...
Reports Q4 revenue $2.07B, consensus $1.97B. “We are pleased to announce another strong quarter for AerCap (AER), completing a year of record operating cash flow and earnings per share. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback